• Knight Therapeutics launched Tavalisse in Mexico for adults with chronic immune thrombocytopenia with inadequate response to prior therapy.
• Move expands its Latin America rollout under a 2022 exclusive commercialization deal with Rigel Pharmaceuticals.
• Mexico marketing authorization was granted in 2024; Brazil clearance followed in May 2026 with a launch planned in 2H 2026.
• Phase III FIT trials showed an 18% stable platelet response on fostamatinib versus 2% on placebo.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Knight Therapeutics Inc. published the original content used to generate this news brief on May 27, 2026, and is solely responsible for the information contained therein.